Katherine Seley-Radtke is an American medicinal chemist who specializes in the discovery and design of novel nucleoside or nucleotide based enzyme inhibitors that may be used to treat infections or cancer.
She has authored over 90 peer-reviewed publications, is an inventor of five issued US patents, and is a professor in the department of chemistry and biochemistry at the University of Maryland, Baltimore County.
A pioneer of the "fleximer" class of nucleoside analogs,[2] Seley-Radtke has designed, synthesized and developed a broad range of enzyme inhibitors that have applications as potential therapeutics in treatment of cancer and of infections with viruses.
Her high school education included a combined program at Gannon University where she carried out a mouse breeding experiment involving over 200 mice in her family home.
She returned to college full-time when her daughters reached junior high, and completed her BA with honors from the University of South Florida in 1992.
Seley-Radtke has been actively involved in diplomatic efforts between Russia and the US Departments of Health and Human Services and Defense to reduce proliferation threats through scientific collaboration.